Clinical Trials
4 trialsNCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT06676891 2025-01-08
Expanded Access Program for GBM Subjects
Rznomics, Inc.
Available
NCT02146066 2016-02-26
DCVax-L EAP
Northwest Biotherapeutics
Available